PRIVATE EQUITY INTERNATIONAL
Cerberus lines up €500m Bayer unit
Cerberus Capital Management, the US turnaround specialist, is reported to be in exclusive talks to buy German drug giant Bayer’s blood products unit for over €500 million.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
- Database
- LP search
- GP search
- Fund search
- Commitments
- Investment Consultant search
- Placement Agent search
- Law Firm search
- Live Fundraising Chart
- Benchmarks
- Institution Profiles Index
- Private Equity Data
- Investor Calendar
- Update your database profile
- Law firm data submission
- Database key terms and methodology
- Fund performance methodology
- Quick Search
- Meet the LP Series
- PEI 300: The World’s Largest Private Equity Firms
- Side Letter
- Friday Letters
- Guest Comment
- Private Equity Investor Intentions and Preferences
- Private Take
- The Democratisation of Private Equity
- Magazine
- LP Perspectives 2026
- Top Private Equity Placement Agents
- Secondaries
- Performance
- Latest News & Analysis
- Rankings & Reports
- Events
- Bookstore
- Podcasts
